CN112535294A - 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 - Google Patents
牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 Download PDFInfo
- Publication number
- CN112535294A CN112535294A CN202011326465.8A CN202011326465A CN112535294A CN 112535294 A CN112535294 A CN 112535294A CN 202011326465 A CN202011326465 A CN 202011326465A CN 112535294 A CN112535294 A CN 112535294A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- taurine
- taurate
- magnesium taurate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 title claims abstract description 43
- 230000036996 cardiovascular health Effects 0.000 title claims abstract description 16
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 229960003080 taurine Drugs 0.000 claims description 29
- 239000013589 supplement Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 47
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 22
- 235000019341 magnesium sulphate Nutrition 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- SDHMGKANHNMOSS-UHFFFAOYSA-N 1-aminoethanesulfonic acid Chemical compound CC(N)S(O)(=O)=O SDHMGKANHNMOSS-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了牛磺酸镁在制备改善心血管健康的营养补充剂中的应用。经过动物实验证明,牛磺酸镁能够改善心血管健康。
Description
技术领域
本发明涉及一种牛磺酸镁在制备改善心血管健康的营养补充剂中的应用,属于食品技术领域。
背景技术
镁是人体内含量最多的阳离子之一,是人体细胞内占第二位(仅次于钾)的阳离子,镁参与蛋白质的合成,镁能激活体内多种酶,能调节神经肌肉和中枢神经系统的活动,保障心机正常收缩,镁几乎参与人体内所有的新陈代谢。人体缺镁可引起许多疾病,反之,镁可治疗上述相关的疾病。作为补充镁离子的首选药—硫酸镁在临床上应用作为广泛。
牛磺酸是人体所必需的十八种氨基酸之一,是一种化学结构简单的含硫氨基酸,为α-氨基乙磺酸,不参与蛋白质组成和代谢,而是以游离形式存在或与胆汁酸形成复合物。牛磺酸在生物体内参与一系列的生理学过程,如与胆汁酸结合、调节渗透压、外源化合物的解毒、细胞膜的稳定、细胞钙流动调节、神经发育、神经兴奋性调节、神经保护、抗氧化和抗心律失常等,具有广泛的生物活性,对血管、神经、肌肉运动、内分泌、免疫等系统发挥良好的调节作用,特别对婴儿大脑和视觉发育有重要的作用。
发明内容
为了克服现有技术的不足,本发明提供了一种牛磺酸镁在制备改善心血管健康的营养补充剂中的应用。
本发明是通过以下技术方案来实现的:
牛磺酸镁在制备改善心血管健康的营养补充剂中的应用。
所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,所述牛磺酸镁是通过以下步骤获得的:
(1)将镁屑和甲醇一起置于反应容器中,加热回流1-2h,然后浓缩蒸干得到白色粉末;
(2)将牛磺酸与水混合制成牛磺酸水溶液,然后与步骤(1)中得到的白色粉末混合,加热回流40-50min后,静置过夜后过滤,得到滤液;
(3)向滤液中加入甲醇,搅拌后在0-4℃中静置24h,再次过滤,将过滤后的澄清液浓缩,得到最后的牛磺酸镁。
所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,所述牛磺酸镁是通过以下步骤获得的:
(1)将镁屑1g和甲醇20-30ml一起置于反应容器中,加热回流1-2h,然后浓缩蒸干得到白色粉末;
(2)将牛磺酸10g与水100ml混合制成10%的牛磺酸水溶液,然后与步骤(1)中得到的白色粉末混合,加热回流40-50min后,静置过夜后过滤,得到滤液;
(3)向滤液中加入甲醇50-80ml,搅拌后在0-4℃中静置24h,再次过滤,将过滤后的澄清液浓缩,得到最后的牛磺酸镁。
所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,所述牛磺酸镁在补充剂中的添加量为10-30%。
经过动物实验证明,牛磺酸镁能够减少血栓,还能够降低血糖,从而改善心血管健康。将牛磺酸镁应用于营养补充剂中,可以改善使用者的心血管健康。
具体实施方式
下面对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
牛磺酸镁的制备方法如下:
(1)将镁屑1g和甲醇20-30ml一起置于反应容器中,加热回流1-2h,然后浓缩蒸干得到白色粉末;
(2)将牛磺酸10g与水100ml混合制成10%的牛磺酸水溶液,然后与步骤(1)中得到的白色粉末混合,加热回流40-50min后,静置过夜后过滤,得到滤液;
(3)向滤液中加入甲醇50-80ml,搅拌后在0-4℃中静置24h,再次过滤,将过滤后的澄清液浓缩,得到最后的牛磺酸镁。
补充剂的制备方法如下:
将牛磺酸镁与补充剂其它成分混合后得到补充剂,其中牛磺酸镁的添加量占补充剂总重量的10-30%。
一、牛磺酸镁补充剂改善静脉血栓的实验
1、材料和方法
1.1实验动物
Wistar种大鼠,清洁级,体重200-250g。
1.2对大鼠体内静脉血栓形成的影响
取大鼠72只,雌雄各半,体重200-250g,随机分为八组,模型组、硫酸镁组、牛磺酸组、阳性组、硫酸镁+牛磺酸组、牛磺酸镁高、中、低剂量组,每组动物9只,给药剂量见表1。模型组灌胃给予溶剂0.5%羧甲基纤维素钠溶液作为对照。阳性组给予的是阿司匹林。硫酸镁+牛磺酸组中硫酸镁和牛磺酸的重量比为1:1。
表1
各组均灌胃相应药液。每天1次,连续7d,末次给药后1h,大鼠以3%戊巴比妥钠腹腔给药麻醉,于腹中线切开皮肤约3cm,分离下腔静脉,于左肾静脉下方用粗线结扎下腔静脉,缝合腹壁。4h后,重新打开腹腔,在结扎下方2cm处夹闭管腔,将该段管腔内血液吸尽,剖开管腔,取出血栓,放在滤纸上,吸干血液,用微量电子天秤称取血栓湿重(mg)。以血栓重量为评价指标,测定各给药组对静脉血栓形成的影响。
1.3统计学处理
实验结果均以x±s表示,采用单因素方差分析进行组间显著性比较,样本均数间比较采用t检验。*表示P<0.05,表明给药组与模型组比较有显著性差异;**表示P<0.01,表明给药组与模型组比较有极显著性差异。
2、结果
表2各个组别血栓的重量
从表2中可以看到,与模型组相比,硫酸镁、牛磺酸、牛磺酸镁均能减少大鼠的血栓湿重,同时,能够看到同时给药硫酸镁和牛磺酸比单独给药硫酸镁或牛磺酸效果差不多,但是在同等剂量下,牛磺酸镁的效果优于硫酸镁和牛磺酸的效果,也优于硫酸镁+牛磺酸组。
二、牛磺酸镁补充剂改善血糖的实验
1、材料和方法
1.1实验动物
昆明种小鼠,体重24-30g。
1.2对正常小鼠体内血糖的影响
将小鼠随机分为八组,模型组、硫酸镁组、牛磺酸组、阳性组、硫酸镁+牛磺酸组、牛磺酸镁高、中、低剂量组,每组动物9只,给药剂量见表1,每天一次,连续30天。模型组灌胃给予溶剂0.5%羧甲基纤维素钠溶液作为对照。阳性组给药胰岛素,硫酸镁+牛磺酸组中硫酸镁和牛磺酸的重量比为1:1。研究各组中血糖水平的变化。
1.3对糖尿病小鼠体内血糖的影响
糖尿病小鼠模型建立:健康雄性昆明种小鼠180只,普通维持饲料适应性喂养1w后,禁食4h,尾静脉取血,采用罗氏血糖仪检测小鼠0h血糖值。灌胃给予2.5g/kg葡萄糖后,检测小鼠0.5、2h血糖值,作为该批次动物基础值。以0、0.5h血糖水平为参考将小鼠随机分为九组,即正常组、模型组、硫酸镁组、牛磺酸组、硫酸镁+牛磺酸组、阳性组组、牛磺酸镁高、中、低剂量组,每组20只。
正常组小鼠继续喂食普通维持饲料,其他八组更换高热能饲料(猪油10%、蔗糖15%、蛋黄粉15%、酪蛋白5%、胆固醇1.2%、胆酸钠0.2%、碳酸氢钙0.6%、石粉0.4%、鼠维持料52.6%)。喂饲3w后,其他八组禁食不禁水24h,腹腔注射链脲酶素(STZ)120mg/kg体重,注射量0.2ml/20g体重,正常对照组给予相同剂量生理盐水腹腔注射。继续给予相应饲料喂饲7d后,禁食4h,检测各组小鼠空腹血糖,以血糖值≥16mmol/L作为高血糖模型成立标准,用于后续实验。
对糖尿病小鼠给药:模型组高血糖小鼠给予大豆油灌胃,阳性组给药胰岛素,硫酸镁+牛磺酸组中硫酸镁和牛磺酸的重量比为1:1,其他组的具体计量见表1,以上各组小鼠继续给予高热能饲料喂饲,正常对照组给予大豆油灌胃,饲喂普通维持饲料,实验持续4w。末次灌胃后,禁食4h,尾静脉取血,检测小鼠血糖值。灌胃给予各组小鼠2.5g/kg葡萄糖,检测小鼠血糖值。
1.3统计学处理
实验结果均以x±s表示,采用单因素方差分析进行组间显著性比较,样本均数间比较采用t检验。*表示P<0.05,表明给药组与模型组比较有显著性差异;**表示P<0.01,表明给药组与模型组比较有极显著性差异。
2、结果
2.1牛磺酸镁对正常小鼠血糖的影响见表3。
表3
从表1可以看出,牛磺酸镁对正常小鼠血糖的影响不大,硫酸镁、牛磺酸镁和硫酸镁+牛磺酸对正常小鼠血糖的影响同样不大。
2.2牛磺酸镁对糖尿病小鼠血糖的影响见表4。
表4
从表4可以看出,与模型组相比,硫酸镁、牛磺酸、牛磺酸镁均能减少小鼠的血糖,同时,能够看到同时给药硫酸镁和牛磺酸比单独给药硫酸镁或牛磺酸效果差不多,但是在同等剂量下,牛磺酸镁的效果优于硫酸镁和牛磺酸的效果,也优于硫酸镁+牛磺酸组。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变形,这些改进和变形也应视为本发明的保护范围。
Claims (4)
1.牛磺酸镁在制备改善心血管健康的营养补充剂中的应用。
2.根据权利要求1所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,其特征是,所述牛磺酸镁是通过以下步骤获得的:
(1)将镁屑和甲醇一起置于反应容器中,加热回流1-2h,然后浓缩蒸干得到白色粉末;
(2)将牛磺酸与水混合制成牛磺酸水溶液,然后与步骤(1)中得到的白色粉末混合,加热回流40-50min后,静置过夜后过滤,得到滤液;
(3)向滤液中加入甲醇,搅拌后在0-4℃中静置24h,再次过滤,将过滤后的澄清液浓缩,得到最后的牛磺酸镁。
3.根据权利要求2所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,其特征是,所述牛磺酸镁是通过以下步骤获得的:
(1)将镁屑1g和甲醇20-30ml一起置于反应容器中,加热回流1-2h,然后浓缩蒸干得到白色粉末;
(2)将牛磺酸10g与水100ml混合制成10%的牛磺酸水溶液,然后与步骤(1)中得到的白色粉末混合,加热回流40-50min后,静置过夜后过滤,得到滤液;
(3)向滤液中加入甲醇50-80ml,搅拌后在0-4℃中静置24h,再次过滤,将过滤后的澄清液浓缩,得到最后的牛磺酸镁。
4.根据权利要求3所述的一种牛磺酸镁在制备改善心血管健康的补充剂中的应用,其特征是,所述牛磺酸镁在补充剂中的添加量为10-30%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011326465.8A CN112535294A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011326465.8A CN112535294A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112535294A true CN112535294A (zh) | 2021-03-23 |
Family
ID=75014766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011326465.8A Pending CN112535294A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112535294A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101291599A (zh) * | 2005-10-20 | 2008-10-22 | 希格马托制药工业公司 | 对骨骼肌供给能量和保护心血管的膳食补充剂 |
US20100158956A1 (en) * | 2007-06-26 | 2010-06-24 | Komorowski James R | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
CN111960972A (zh) * | 2020-08-28 | 2020-11-20 | 许昌远志生物科技有限公司 | 牛磺酸镁盐及牛磺酸镁配合物的制备工艺与应用 |
-
2020
- 2020-11-24 CN CN202011326465.8A patent/CN112535294A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101291599A (zh) * | 2005-10-20 | 2008-10-22 | 希格马托制药工业公司 | 对骨骼肌供给能量和保护心血管的膳食补充剂 |
US20100158956A1 (en) * | 2007-06-26 | 2010-06-24 | Komorowski James R | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
CN111960972A (zh) * | 2020-08-28 | 2020-11-20 | 许昌远志生物科技有限公司 | 牛磺酸镁盐及牛磺酸镁配合物的制备工艺与应用 |
Non-Patent Citations (1)
Title |
---|
苗宇: ""牛磺酸镁合成与质量控制研究"", 《硕士论文》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0185759A4 (en) | ELECTROLYTE SOLUTIONS AND THEIR USE (IN VIVO). | |
CN1692782A (zh) | 降压好酸奶片 | |
US3928135A (en) | Process for the production of glucose polymers | |
CN103864950B (zh) | 一种低分子坛紫菜多糖铁复合物的制备方法及其应用 | |
CN105747235B (zh) | 一种能改善代谢综合征症状的饮食组合物 | |
EP1172373B1 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
CN110772630A (zh) | 活化胰岛素受体及调控血糖的复合苦瓜肽口服液及制备方法 | |
CN112535294A (zh) | 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 | |
US3914410A (en) | Method for preparing sucrose composition containing chromium III salt | |
JPH04207173A (ja) | 食物繊維含有デキストリンの製造法 | |
CN1806668A (zh) | 从蚕豆、绿豆淀粉加工排放水中提取复合保健功能因子的方法 | |
JP4646550B2 (ja) | ミネラル含有剤とその用途 | |
CN112493491A (zh) | 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 | |
CN114287638A (zh) | 一种小分子复合寡肽及其制备方法和应用 | |
TWI690505B (zh) | 胺基酸快速螯合鈣之方法 | |
CN1221268C (zh) | 镁钙离子复合制剂及其生产工艺 | |
CN102342400A (zh) | 高钙木糖醇 | |
CN112047866A (zh) | 一种牛磺酸的新合成工艺 | |
CN111518854A (zh) | 一种魔芋精粉多酶酶解物及其制备方法 | |
CN114875103B (zh) | 一种小肽螯合钙及其制备方法和用途 | |
CN111990649A (zh) | 一种鱿鱼水溶性黑色素螯合钙盐的制备方法 | |
CN101229218B (zh) | 用于治疗糖尿病的钒复方组合物及其制造方法 | |
CN114317635A (zh) | 一种制备低密度抗消化淀粉的方法 | |
JP2009013088A (ja) | 脂肪細胞分化抑制剤 | |
CN114685320B (zh) | 胍基丁胺牛磺酸盐及其制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210323 |
|
RJ01 | Rejection of invention patent application after publication |